As healthcare transforms from volume to value-based reimbursement, life sciences companies and payers are also beginning to partner and explore value-based programs that tie reimbursement to the value/outcomes a therapy can deliver.
In this session, a senior industry consultant teams with a pharmaceutical executive versed in data and partnership to discuss emerging trends, challenges, and opportunities in RWD analytics, and the evolution of value-based programs in healthcare.
• What is RWD? Why is it important to life sciences companies and their customers? And, specifically, what role will it play in value-based programs?
• What are the current barriers to designing and operationalizing value-based programs between life sciences companies and payers?
• What are the partnership opportunities and necessary capabilities/technologies that can accelerate the design, implementation, and scaling of value-based programs?